Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy

Yachiyo Kuwatsuka, Akio Kohno, Seitaro Terakura, Shigeki Saito, Kazuyuki Shimada, Takahiko Yasuda, Yoshihiro Inamoto, Koichi Miyamura, Masashi Sawa, Makoto Murata, Takahiro Karasuno, Shuichi Taniguchi, Koji Nagafuji, Yoshiko Atsuta, Ritsuro Suzuki, Mariko Fukumoto, Tomoki Naoe, Yoshihisa Morishita

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

We aimed to evaluate the efficacy and safety of allogeneic hematopoietic stem cell transplantation with targeted oral busulfan (BU) and cyclophosphamide (CY) in a phase II study. Busulfan (1.0 mg/kg) was given initially in six doses. Based on the estimated concentration at steady state after the first dose of BU, subsequent (7th-16th) doses were adjusted to obtain a targeted overall concentration at steady state of 700-900 ng/mL. The primary endpoint was 1-year overall survival (OS). Fifty patients were registered and 46 (median age, 53 years; range, 18-62 years) received planned transplant, including 24 with AML, 16 with myelodysplastic syndrome, and six with CML. Fourteen patients were categorized as standard risk. Nineteen patients received transplant from human leukocyte antigen-identical siblings, 27 from unrelated donors. The BU dose required reduction in 32 patients and escalation in six patients. One-year OS was 65% (95% confidence interval, 50-77%). Cumulative incidence of hepatic sinusoidal obstruction syndrome was 11%. One-year transplant-related mortality was 18%. Both OS and transplant-related mortality were favorable in this study, including patients of older age and with high risk diseases. Individual dose adjustment based on BU pharmacokinetics was feasible and effective in the current phase II study. This trial is registered in the University Hospital Medical Information Network Clinical Trial Registry System (UMIN-CTR, ID:C000000156).

Original languageEnglish
Pages (from-to)1688-1694
Number of pages7
JournalCancer science
Volume103
Issue number9
DOIs
Publication statusPublished - 09-2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy'. Together they form a unique fingerprint.

Cite this